邻氨基三氟甲基酮 | 205756-47-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 邻氨基三氟甲基酮
• 英文名称: o-aminotrifluoromethyl ketone
• 英文别名: 1-(6-Amino-2,3-difluoro-phenyl)-2,2,2-trifluoro-ethanone；1-(6-amino-2,3-difluorophenyl)-2,2,2-trifluoroethanone
• CAS: 205756-47-4
• 化学式: C₈H₄F₅NO
• 分子量: 225.118
• InChiKey: VSYPGVRXKMHOGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  邻氨基三氟甲基酮 在 4β-morpholinocaran-3α-ol 、 溶剂黄146 、 苯磺酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲苯 、 xylene 为溶剂， 反应 16.0h， 生成 化合物 T27204
  参考文献：
  名称：

  An Efficient Chiral Moderator Prepared from Inexpensive (+)-3-Carene:  Synthesis of the HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor DPC 963

  摘要：

  [GRAPHICS]The beta-amino alcohol 4 beta-morpholinocaran-3 alpha-ol is prepared by addition of morpholine to alpha-3,4-epoxycarane utilizing anhydrous magnesium bromide as Lewis acid promoter. The enantiopure amino alcohol is uniquely effective as a chiral moderator for the addition of lithium cyclopropylacetylide to an unprotected N-acylketimine. This reaction provides an efficient route to the second generation NNRTI drug candidate DPC 963.

  DOI：

  10.1021/ol006321x
• 作为产物：
  描述：

  3,4-二氟苯胺 在 盐酸 、 正丁基锂 、 TEA 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 为溶剂， 反应 6.5h， 生成 邻氨基三氟甲基酮
  参考文献：
  名称：

  Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors

  摘要：

  Efavirenz (SUSTIVA(TM)) is a potent non-nucleoside reverse transcriptase inhibitor. Due to the observation of breakthrough mutations of the reverse transcriptase enzyme during Efavirenz therapy, we sought to develop an optimized second generation series. To that end, SAR of the substituents on the aromatic ring was undertaken and the results are summarized here. The 5,6-difluoro (4f) and the 6-methoxy (4m) substituted benzoxazinones were determined to be equipotent, and as a result such substitution patterns will be incorporated in second generation scaffolds. (C) 1999 DuPont Pharmaceuticals. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00486-2

文献信息

• Proline potassium salt: a superior catalyst to synthesize 4-trifluoromethyl quinoline derivatives via Friedlander annulation
  作者：Xiao Long Du、Biao Jiang、Yuan Chao Li

  DOI：10.1016/j.tet.2013.06.017

  日期：2013.9

  Proline potassium salt was successfully firstly used to catalyze the Friedlander annulation toward the synthesis of 4-trifluoromethyl-substituted quinolines from the substituted 2-trifluoroacetyl anilines and variety carbonyl compounds under mild conditions in good to excellent yields. This catalyst provides several advantages, such as shorter reaction time, high regioselectivity, functional group

  脯氨酸钾盐首先成功地用于催化弗里德兰德环化反应，在温和的条件下以良好或优异的收率由取代的2-三氟乙酰基苯胺和各种羰基化合物合成4-三氟甲基取代的喹啉。该催化剂具有许多优点，例如反应时间短，区域选择性高，官能团耐受性强和底物范围广。
• Expanded-Spectrum Nonnucleoside Reverse Transcriptase Inhibitors Inhibit Clinically Relevant Mutant Variants of Human Immunodeficiency Virus Type 1
  作者：Jeffrey W. Corbett、Soo S. Ko、James D. Rodgers、Susan Jeffrey、Lee T. Bacheler、Ronald M. Klabe、Sharon Diamond、Chii-Ming Lai、Shelley R. Rabel、Jo Anne Saye、Stephen P. Adams、George L. Trainor、Paul S. Anderson、Susan K. Erickson-Viitanen

  DOI：10.1128/aac.43.12.2893

  日期：1999.12

  A research program targeted toward the identification of expanded-spectrum nonnucleoside reverse transcriptase inhibitors which possess increased potency toward K103N-containing mutant human immunodeficiency virus (HIV) and which maintain pharmacokinetics consistent with once-a-day dosing has resulted in the identification of the 4-cyclopropylalkynyl-4-trifluoromethyl-3,4-dihydro-2(1 H )quinazolinones DPC 961 and DPC 963 and the 4-cyclopropylalkenyl-4-trifluoromethyl-3,4-dihydro-2(1 H )quinazolinones DPC 082 and DPC 083 for clinical development. DPC 961, DPC 963, DPC 082, and DPC 083 all exhibit low-nanomolar potency toward wild-type virus, K103N and L100I single-mutation variants, and many multiply amino acid-substituted HIV type 1 mutants. This high degree of potency is combined with a high degree of oral bioavailability, as demonstrated in rhesus monkeys and chimpanzees, and with plasma serum protein binding that can result in significant free levels of drug.

  摘要：针对鉴定对K103N突变型人类免疫缺陷病毒（HIV）具有增强效力且保持一日一次剂量的药代动力学一致性的扩展谱非核苷类逆转录酶抑制剂的研究项目已经取得成果，发现了4-环丙炔基-4-三氟甲基-3,4-二氢-2(1H)喹唑啉酮DPC 961和DPC 963，以及4-环丙烯基-4-三氟甲基-3,4-二氢-2(1H)喹唑啉酮DPC 082和DPC 083用于临床开发。DPC 961、DPC 963、DPC 082和DPC 083均对野生型病毒、K103N和L100I单突变变种以及许多多种氨基酸替换的HIV-1突变体表现出低纳摩尔级别的效力。这种高度的效力与口服生物利用度高度结合，如在恒河猴和黑猩猩中展示的那样，并且具有可以导致显著药物自由水平的血浆血清蛋白结合。
• Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
  申请人：——

  公开号：US20010044540A1

  公开（公告）日：2001-11-22

  This invention relates generally to the asymmetric synthesis of quinazolin-2-ones that are useful as inhibitors of HIV reverse transcriptase. The synthesis is accomplished through the chiral ligand mediated addition of cyclopropylacetylide.

  这项发明通常涉及对喹唑啉-2-酮的不对称合成，这些化合物可用作HIV逆转录酶的抑制剂。合成是通过手性配体介导的环丙基乙炔加成实现的。
• Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors
  作者：Jeffrey W. Corbett、Soo S. Ko、James D. Rodgers、Lisa A. Gearhart、Nicholas A. Magnus、Lee T. Bacheler、Sharon Diamond、Susan Jeffrey、Ronald M. Klabe、Beverly C. Cordova、Sena Garber、Kelly Logue、George L. Trainor、Paul S. Anderson、Susan K. Erickson-Viitanen

  DOI：10.1021/jm990580e

  日期：2000.5.1

  A series of 4-alkenyl and 4-alkynyl-3,4-dihydro-4-(trifluoromethyl)-2-(1H)-quinazolinones were found to be potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) of human immunodeficiency virus type-1 (HIV-1). The 4-alkenyl-3,4-dihydro-4-(trifluoromethyl) quinazolinones DPC 082 and DPC 083 and the 4-alkynyl-3,4-dihydro-4-(trifluoromethyl) (LK)-quinazolinones DPC 961 and DPC 963 were found to exhibit low nanomolar potency toward wild-type RF virus (IC90 = 2.0, 2.1, 2.0, and 1.3 nM, respectively) and various single and many multiple amino acid substituted HIV-1 mutant viruses.-The increased potency is combined with favorable plasma serum protein binding as demonstrated by improvements in the percent free drug in human plasma when compared to efavirenz: 3.0%, 2.0%, 1.5% 2.8%, and 0.2- 0.5% for DPC 082, DPC 083, DPC 961, DPC 963, and efavirenz, respectively.
• 3,3a-Dihydropyrano[4,3,2- de ]quinazolin-2(1 H )-ones are potent non-nucleoside reverse transcriptase inhibitors
  作者：Jeffrey W Corbett、Senliang Pan、Jay A Markwalder、Beverly C Cordova、Ronald M Klabe、Sena Garber、James D Rodgers、Susan K Erickson-Viitanen

  DOI：10.1016/s0960-894x(00)00624-7

  日期：2001.1

  A series of unique 3,3a-dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones and a 2a,5-dihydro-2H-thieno[4,3,2-de]quinazoline-4(3H)-thione were found to be HIV-1 non-nucleoside reverse transcriptase inhibitors. One of these compounds, as the racemate, possessed an IC90 = 4.6 nM against wild-type virus in a whole cell antiviral assay and had an IC90 = 76 and 897 nM against the clinically significant K103N and K103N/L100I mutant viruses, respectively. (C) 2001 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.